Using 68Ga-Pentixafor PET/CT to improve diagnosis and treatment of primary aldosteronism
68Ga-Pentixafor PET/CT in the Diagnosis of Primary Aldosteronism and Pre-postoperative of Superselective Adrenal Artery Embolization
NA · First Affiliated Hospital of Fujian Medical University · NCT05188872
This study is testing a new imaging method to see if it can help doctors better diagnose and treat people with primary aldosteronism, a condition that causes high blood pressure.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 19 Years to 90 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Fujian Medical University (other) |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT05188872 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of 68Ga-Pentixafor PET/CT imaging to enhance the diagnosis and treatment strategies for primary aldosteronism, a common cause of secondary hypertension. It aims to provide a non-invasive alternative to adrenal vein sampling (AVS), which has a success rate of only 80%. The study will evaluate changes in adrenal tissue structure and function before and after superselective adrenal artery embolization (SAAE) using this imaging technique. By improving diagnostic accuracy, the study seeks to facilitate better management of patients with primary aldosteronism.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with suspected or newly diagnosed primary aldosteronism.
Not a fit: Patients who are pregnant or unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses and improved treatment outcomes for patients with primary aldosteronism.
How similar studies have performed: While the use of PET imaging in this context is innovative, similar imaging techniques have shown promise in other areas of endocrinology, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult population (aged 18 years or order); * patients with suspected or new diagnosed Primary aldosteronism (supporting evidence may include MRI, CT, laboratory tests); * patients who had scheduled 68Ga-BNU-PSMA PET/CT scan; * patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee; * healthy volunteers(aged 18 years or order). Exclusion Criteria: * patients with pregnancy; * the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where this trial is running
Fuzhou, Fujian
- Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (RECRUITING)
Study contacts
- Study coordinator: Weibing Miao, MD
- Email: miaoweibing@126.com
- Phone: 86-0591-87981618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Positron-Emission Tomography